• All sections
  • C - Chemistry; metallurgy
  • C07D - Heterocyclic compounds
  • C07D 263/34 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Patent holdings for IPC class C07D 263/34

Total number of patents in this class: 254

10-year publication summary

23
15
21
16
18
15
16
18
12
1
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Principal owners for this class

Owner
All patents
This class
Theravance Biopharma R&D IP, LLC
517
27
Pro Farm Group, Inc.
108
10
DSM IP Assets B.V.
5819
8
Astellas Pharma Inc.
1122
8
Siemens Medical Solutions USA, Inc.
1544
7
Boehringer Ingelheim International GmbH
4756
6
Merck Patent GmbH
5847
5
Takeda Pharmaceutical Company Limited
2945
5
Blade Therapeutics, Inc.
21
4
Kissei Pharmaceutical Co., Ltd.
198
4
Nippon Shinyaku Co., Ltd.
318
4
Otsuka Pharmaceutical Co., Ltd.
1538
4
Janssen Pharmaceutica N.V.
3624
3
Syngenta Crop Protection AG
4894
3
Allergan, Inc.
2445
3
Bayer Pharma AG
1085
3
Amgen Inc.
3897
3
Arizona Board of Regents on behalf of Arizona State University
2450
3
Incyte Corporation
961
3
Rutgers, The State University of New Jersey
1843
3
Other owners 138